argenx SE 2021 SR
The report highlights argenx's inaugural ESG efforts for 2021, focusing on its mission to improve the lives of patients with severe rare diseases through immunology innovation. Key achievements include the approval of VYVGART in the U.S. and Japan for generalized myasthenia gravis and the expansion of its Immunology Innovation Program. The company doubled its workforce to 854 employees and emphasized diversity, with 58% of the total workforce being female. argenx also launched patient-centric initiatives like My VYVGART Path and the A Mystery to Me documentary to support the rare disease community.
Company: argenx SE
Sector: Manufacturing
Country: Netherlands
Year: 2021
Type: SR
Pages: 34
Back to company
argenx SE
ESG Report
The report highlights argenx's inaugural ESG efforts for 2021, focusing on its mission to improve the lives of patients with severe rare diseases through immunology innovation. Key achievements include the approval of VYVGART in the U.S. and Japan for generalized myasthenia gravis and the expansion of its Immunology Innovation Program. The company doubled its workforce to 854 employees and emphasized diversity, with 58% of the total workforce being female. argenx also launched patient-centric initiatives like My VYVGART Path and the A Mystery to Me documentary to support the rare disease community.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees